山东威高血液净化制品股份有限公司 首次公开发行股票主板上市公告书 提示性公告 保荐人（主承销商）：华泰联合证券有限责任公司 扫描二维码查阅公告全文 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，山东威高血液净化制品股份有限公司（以下简 称"威高血净"、"发行人"或"公司"）人民币普通股股票将于 2025 年 5 月 19 日在 上海证券交易所主板上市，上市公告书全文和首次公开发行股票的招股说明书全 文披露于上海证券交易所网站（http://www.sse.com.cn/）和符合中国证监会规定 条件网站（中证网：http://www.cs.com.cn；中国证券网：http://www.cnstock.com； 证券时报网：http://www.stcn.com；证券日报网：http://www.zqrb.cn；经济参考网： http://www.jjckb.cn）披露，供投资者查阅。 一、上市概况 （五）首次公开发行股份数量：4,113.9407 万股，本次发行全部为新股，无 老股转让 1 （一）股票简称：威高血 ...

股票简称：威高血净 股票代码：603014 山东威高血液净化制品股份有限公司 （Shandong Weigao Blood Purification Products Co., Ltd.） （威海火炬高技术产业开发区威高西路 7 号） 首次公开发行股票主板上市公告书 保荐人（主承销商） （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 二〇二五年五月十六日 山东威高血液净化制品股份有限公司（以下简称"威高血净"、"本公司"、 "发行人"或"公司"）股票将于 2025 年 5 月 19 日在上海证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 本上市公告书中若出现总数与各分项数值之和尾数不等的情况，均为四舍五 入尾差所致。 1 山东威高血液净化制品股份有限公司 上市公告书 第一节 重要声明与提示 山东威高血液净化制品股份有限公司 上市公告书 特别提示 一、重要声明与提示 本公司及全体董事、高级管理人员保证上市公告书所披露信息的真实、准确、 完整，承诺上市公告书不存在虚假记载、误导性陈述或 ...

山东威高血液净化制品股份有限公司 章程 (草案) 二〇二三年十二月 4-2-1 山东威高血液净化制品股份有限公司 章程 目录 | 第一章 总 则 | | --- | | 第二章 经营宗旨和范围 | | 第三章 股份 . | | 第一节 股份发行 … | | 第二节 股份增减和回购 | | 第三节 股份转让 … | | 第四章 股东和股东大会 | | 第一节 股东 . | | 第二节 股东大会的一般规定 | | 第三节 股东大会的召集 ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 12 | | 第四节 股东大会的提案与通知 …………………………………………………………………………………… 13 | | 第五节 股东大会的召开……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………15 | | 第六节 股东大会的表决和决议 … | | 第五章 董 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、完整、及时，没有虚假记 载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，山东威高血液净化制品股份有限公司（以下简称"威高血净"、"发行 人"或"公司"）人民币普通股股票将于2025年5月19日在上海证券交易所主板上市，上市公告书全文和首 次公开发行股票的招股说明书全文披露于上海证券交易所网站（http://www.sse.com.cn/）和符合中国证 监会规定条件网站（中证网：http://www.cs.com.cn；中国证券网：http://www.cnstock.com；证券时报 网：http://www.stcn.com；证券日报网：http://www.zqrb.cn；经济参考网：http://www.jjckb.cn）披露，供 投资者查阅。 一、上市概况 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市初期的投资风险，广大投资者应 充分了解风险、理性参与新股交易。具体如下： （一）涨跌幅限制放宽带来的股票交易风险 根据《上海证券交易所交易规则（2023年修订）》， ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [7][4]. Core Views - The pharmaceutical sector underperformed the overall market this week, with a 1.01% increase compared to the total A-share market's 2.29% rise. The medical device sector led the gains [1][31]. - The report highlights the U.S. government's recent administrative order aimed at providing "Most Favored Nation" pricing for prescription drugs, which may face judicial challenges similar to previous attempts in 2020 [2][28]. - The U.S. healthcare spending reached $4.46 trillion in 2022, accounting for 17.5% of GDP, with government-funded programs like Medicare and Medicaid being significant contributors to this expenditure [16]. Summary by Sections Market Performance - The overall A-share market increased by 2.29%, with the Shanghai and Shenzhen 300 index rising by 2.00%. The biotechnology sector's performance was weaker, with a 1.01% increase [1][31]. - Individual stocks showed significant variances, with JinHao Medical leading with a 24.38% increase, while ST HuLuWa faced an 18.29% decline [35][31]. U.S. Drug Pricing Reform - The U.S. government issued an executive order on May 12, 2025, promoting "Most Favored Nation" pricing for prescription drugs, which aims to lower U.S. drug prices based on international benchmarks [15][28]. - The report notes that the implementation of this order may be limited in the short term due to potential legal challenges and the need for further details [2][28]. Company Ratings and Predictions - Key companies rated as "Outperform" include: - Mindray Medical: Strong R&D and sales capabilities, benefiting from domestic medical infrastructure [42]. - WuXi AppTec: A comprehensive service platform for new drug development, poised to benefit from the global outsourcing market [42]. - New Industries: A leader in chemiluminescence immunoassay, with strong growth prospects [42]. - Other notable mentions include Aide Biological, ZhenDe Medical, and Kangfang Biological, all rated "Outperform" [4][42][44]. Valuation Metrics - The TTM P/E ratio for the pharmaceutical and biotechnology sector is 32.26x, compared to the overall A-share market's 18.43x. Sub-sectors like chemical pharmaceuticals and biological products have higher P/E ratios of 37.86x and 38.40x, respectively [37][38].

Core Viewpoint - The new share issuance results of Weigao Blood Purification indicate a strong interest from online investors, with a total subscription amount of 707.77 million yuan and a low abandonment rate of 0.544% [1][2][3]. Summary by Category Subscription Details - Online investors subscribed for 26,708,400 shares, amounting to 707.77 million yuan, while offline investors subscribed for 12,512,100 shares, totaling 331.57 million yuan [2][3]. - The total number of shares issued was 41,139,400, with an issuance price of 26.5 yuan per share [3]. Abandonment Rates - The online abandonment quantity was 146,100 shares, with an abandonment amount of 3.87 million yuan, while offline abandonment was minimal at 695 shares, amounting to 18,400 yuan [1][2]. - The overall abandonment rate for online subscriptions was 0.544%, with the abandonment amount being 387.16 thousand yuan [1][3]. Market Context - In the context of recent new share issuances, Weigao Blood Purification ranked among the top in terms of abandonment quantity and rate, with notable competitors including Tian You Wei and Jiang Shun Technology [3]. - The online issuance final winning rate was 0.03215719%, and the strategic allocation was 1,772,100 shares [3].

一、证券市场回顾 南财金融终端数据显示，上周（5月6日-5月9日,下同），上证综指周内上涨1.92%，收于3342.0点，最高3359.73点；深证成指周内上涨2.29%，收于10126.83 点，最高10248.98点；创业板指周内上涨3.27%，收于2011.77点，最高2036.1点。在全球市场中，主要指数有涨有跌。纳斯达克综指下跌0.27%，道琼斯工业 指数下跌0.16%，标普500下跌0.47%。亚太地区，恒生指数上涨1.61%，日经225指数上涨1.83%。 二、新股申购情况 上周有3只新股发行,详情见下表： | 股票代码 | 股票简称 | 申购日期 | | --- | --- | --- | | 301595.SZ | 太力科技 | 20250508 | | 603014.SH | 威高血净 | 20250508 | | 688755.SH | 汉邦科技 | 20250507 | 三、融资融券情况 上周共有16条开始执行回购公告，其中执行金额最多的5条公告为： | 证券代码 | 证券简称 | | --- | --- | | 601877 | 正泰电器 | | 002145 | 中核钛白 | | ...

Group 1: New Stock Market Performance - The average increase of new stocks listed since 2024 is approximately 3.0%, with about 82.9% of new stocks showing positive returns[1] - The average increase for new stocks on the North Exchange is 5.5%, with around 96.2% of new stocks experiencing gains[5] - The average issuance price-to-earnings ratio for new stocks last week was 24.2X, with a subscription success rate of 0.0267%[4] Group 2: Market Trends and Recommendations - The current market is in a transformation window, with significant policy clarity expected to gradually materialize, indicating a potential new active cycle[2] - Caution is advised due to ongoing external disturbances, including geopolitical tensions and tariff negotiations, which may lead to market fluctuations[2] - Focus should be on near-term new stocks that have undergone sufficient adjustment and offer relatively high cost-performance ratios, particularly those benefiting from hot themes or policy expectations[3] Group 3: Upcoming New Stocks - This week, five new stocks are set to complete subscriptions, including one from the Sci-Tech Innovation Board and two from the Growth Enterprise Market[7] - One stock, Guqi Down Material, is expected to start pricing inquiries, being a significant supplier of duck down and goose down materials[8]

Industry Overview - The blood purification sector is emerging as a "golden track" within the rapidly growing healthcare industry, driven by significant market potential and growth prospects [1] - The prevalence of chronic kidney disease (CKD) poses a major public health challenge globally, with over 130 million CKD patients in China, leading to a sustained high demand for blood purification treatments [1][2] Market Growth - The number of blood dialysis patients in China increased from 248,000 in 2012 to 844,300 in 2022, with a compound annual growth rate (CAGR) of 13.03%. It is projected to exceed 1.3 million by 2025 [2] - The blood dialysis medical device market in China reached 14.5 billion yuan in 2023 and is expected to surpass 20 billion yuan by 2025, driven by an expanding patient base and advancements in technology [2] Company Profile: Weigao Blood Purification - Weigao Blood Purification (603014) has launched its A-share online subscription, indicating its upcoming entry into the A-share market [1] - The company has a strong research and development (R&D) capability, with R&D investments of 153 million yuan, 183 million yuan, 155 million yuan, and 81.04 million yuan from 2021 to the first half of 2024, representing 5.27%, 5.34%, 4.38%, and 4.98% of its revenue respectively [3] - Weigao has developed proprietary technologies in blood dialysis, achieving international advanced levels in key performance indicators [3] Product Portfolio - Weigao offers a comprehensive product line in both blood dialysis and peritoneal dialysis, including blood dialysis machines, blood dialysis tubes, and peritoneal dialysis solutions, enhancing service efficiency and patient convenience [4] - The company has a strong market presence, covering over 6,000 hospitals and dialysis centers across 31 provinces in China, with a leading market share of 32.5% in blood dialysis devices [4] Financial Performance - Weigao's revenue grew from 2.911 billion yuan in 2021 to 3.532 billion yuan in 2023, with net profits increasing from 260 million yuan to 442 million yuan during the same period [5] - The company plans to utilize funds raised from its A-share listing to enhance production capacity and R&D capabilities, particularly in new dialysis membrane materials [5] Investment Potential - Weigao Blood Purification is positioned as a high-value investment opportunity due to its leading technology, comprehensive product offerings, strong market competitiveness, and solid financial performance [6] - The company aims to expand its market share both domestically and internationally, particularly in countries involved in the "Belt and Road" initiative [5][6]

证券研究报告 | 行业周报 gszqdatemark 2025 05 10 年 月 日 医药生物 【周专题&周观点】【总第 396 期】产线齐全、技术领先，国产血净龙头绘新篇 一、当周（5.6-5.9）回顾与周专题： 当周（5.6-5.9）申万医药指数环比+1.01%，跑输创业板指数，跑输沪深 300 指数。本 周周报，我们梳理了威高血净招股书，供各位投资者参考。 二、近期复盘： 1、当周表现：本周市场（节后交易四天）在过节期间多个利好刺激下，高开后连续震 荡。医药指数这边，走势类似。结构上看，脑机接口、外骨骼机器人、部分减肥链、少 量低位创新药有相对亮眼表现，其他都是个股逻辑为主，前期强势的大部分创新药标的 有所回调。 2、原因分析：本周市场高开主要受五一节期间多个利好刺激带动。节后，前期调整了 一段时间的科技风格资产回归，创新药资金被分流（近期创新药和其他科技资产"跷跷 板"），叠加美国那边部分信息扰动（关税、药价、FDA 等），大部分创新药标的在本周 有所回调。因为科技风格资产反弹，受市场风格映射影响，脑机接口、外骨骼机器人等， 表现亮眼。部分减肥链偏主题标的表现较好，其他表现好的都是个股逻辑，虽然这周 ...